Pfizer and Valneva Announce Lyme Disease Vaccine Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Pfizer (PFE) and Valneva (VALN) announced topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: In the pre-specified analyses: Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm; Efficacy of 74.8% from 1-day post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm; Fewer than anticipated Lyme disease cases were accrued over the study period, and the pre-determined statistical criterion was not met in the first pre-specified analysis. Given the clinically meaningful efficacy and the fact that the 95% confidence interval lower bound was above 20 in the second pre-specified analysis, Pfizer is confident in the vaccine's potential and is planning submissions to regulatory authorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.850
Low
24.00
Averages
28.56
High
35.00
Current: 25.850
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's Future Investments and Dividend Analysis
- Dividend Yield: Pfizer's recent dividend yield of 6.7% not only provides investors with a steady cash flow but also attracts long-term investors seeking income, thereby enhancing market interest in its stock.
- Analyst Rating Discrepancies: MarketWatch tracked 28 analyst ratings for Pfizer, with 9 recommending 'buy', 15 suggesting 'hold', and 3 advising 'sell', indicating a cautious market sentiment and an overall consensus to 'hold', reflecting uncertainty about future performance.
- R&D Pipeline Progress: Pfizer has 96 drugs in development, with 31 in late-stage trials, particularly the Mevpro-1 phase 3 trial for metastatic castration-resistant prostate cancer, with results expected in the second half of 2026, which could yield an upside of about $2 per share if successful, showcasing Pfizer's strategic focus in oncology.
- Acquisition and Growth Potential: By acquiring companies like Metsera to bolster its GLP-1 drug development, Pfizer is addressing upcoming patent expirations; despite current challenges, its diverse growth catalysts and robust R&D pipeline support future business growth, highlighting its potential in the weight-loss drug market.
See More
Pfizer to Host Investor Webcast at Jefferies Conference
- Webcast Announcement: Pfizer Inc. will host a webcast on June 3, 2026, at 2:00 p.m. EDT during the Jefferies Global Healthcare Conference in New York, featuring CEO Albert Bourla, which is expected to draw significant investor and public interest.
- Access Information: Investors can visit Pfizer's website to access the webcast, with registration details available starting today, ensuring participants can smoothly listen to and view this important discussion.
- Replay and Transcript: The transcript and replay of the webcast will be made available on Pfizer's website within 24 hours after the live discussion, accessible for at least 90 days, allowing investors who could not attend live to catch up on the information.
- Company Mission and Vision: Pfizer emphasizes its commitment to applying science and global resources to provide innovative therapies, highlighting its standards for quality, safety, and value in healthcare product development, showcasing its responsibility as a leading biopharmaceutical company.
See More
FDA Advisory Panel to Discuss 2026-2027 COVID Vaccine Composition
- Vaccine Target Selection: The FDA's Vaccines and Related Biological Products Advisory Committee will vote this week on whether to select the SARS-CoV-2 subvariant XFG as the target for the 2026-2027 COVID vaccines, a decision that will directly influence future vaccine development directions.
- Variant Advantage Analysis: The XFG variant, which emerged from the JN.1 variant, is currently one of the dominant COVID strains in the U.S. and internationally, possessing a growth advantage over the previously dominant LP.8.1 variant, indicating the need for timely vaccine updates to address new challenges.
- Vaccine Production Readiness: In briefing documents released ahead of the meeting, the FDA noted that all licensed COVID vaccine manufacturers have indicated their readiness to produce XFG-targeting vaccines in time for the 2026-27 vaccination season, demonstrating the industry's ability to respond quickly to new variants.
- Vaccine Design Recommendations: Based on last year's VRBPAC recommendations, the FDA has advised vaccine manufacturers to design monovalent COVID vaccines targeting JN.1, preferably LP.8.1, to ensure that vaccines are timely updated to respond to the then-dominant strains, enhancing public health response capabilities.
See More
BridgeBio Pharma Shares Drop After Downgrade by Raymond James
- Downgrade Impact: Raymond James downgraded BridgeBio Pharma (BBIO) from Outperform to Market Perform, primarily due to the anticipated impact of Pfizer's heart drug Vyndamax losing exclusivity, suggesting that BBIO's stock is unlikely to sustain upward momentum amid growing market concerns.
- Increased Competitive Risks: Analyst Martin Auster indicated that with Vyndamax's loss of exclusivity, Attruby's market share could be jeopardized, predicting that new patient starts will become challenging beyond 2031, despite BBIO's efforts to establish a differentiated clinical profile among certain prescribers.
- Market Pressure Expectations: Auster expects that as Vyndamax's exclusivity nears its end, the ATTR-CM therapy market will increasingly rely on formulary-driven dynamics, which may exert greater pressure on TTR stabilizers, potentially undermining BBIO's revenue diversification strategy.
- Price Target Removal: The analyst has removed the $89 price target for BBIO, reflecting a cautious outlook on the company's growth potential, indicating that in a payer-driven market environment, BBIO will need to exert significant efforts to maintain its market position.
See More
Dow Jones Index Celebrates 130th Anniversary with Key Stock Insights
- Dow Component Changes: Since its establishment in 1896, the Dow Jones Index has seen significant changes in its components, with recent additions like Nvidia and Amazon reflecting economic evolution, shifting investor perception from traditional low-growth stocks to a modern blend of growth and value stocks.
- Nvidia's Dividend Surge: On May 20, Nvidia raised its quarterly dividend from $0.01 to $1 per share, a staggering 2400% increase, which, despite a current yield of only 0.5%, attracts investors seeking passive income and indicates a shift towards a more stable earnings model amid surging AI demand.
- Visa's Strong Financial Performance: Despite economic uncertainties, Visa achieved a 9% increase in payment volume in its latest quarter, with valuations at 30 times free cash flow and 29 times earnings, showcasing the resilience of its business model and providing a compelling buying opportunity for investors despite stock price declines.
- Procter & Gamble's Rising Dividend Yield: Procter & Gamble raised its dividend for the 70th consecutive year in April, with a current yield of 3%, and despite challenges in volume growth, its strong brand portfolio positions it as an ideal choice for risk-averse investors, trading at a P/E of just 21, below its 10-year average of 25.4.
See More
Nvidia Makes Significant Dividend Increase
- Dividend Surge: Nvidia raised its quarterly dividend from $0.01 to $1 per share on May 20, marking a staggering 2,400% increase, which, despite a low yield of 0.5%, makes it more attractive for investors seeking passive income.
- Market Share Expansion: Nvidia has broadened its market share in data centers by delivering new rack-scale solutions, including multi-chip systems to Anthropic, OpenAI, Oracle, and SpaceX on May 18, indicating strong growth potential amid surging AI demand.
- Visa Investment Opportunity: Despite a 6.2% decline in Visa's stock year-to-date, its reasonable valuation at 30 times free cash flow and 29 times earnings presents an excellent buying opportunity, with double-digit revenue and earnings growth reflecting its robust business model.
- Procter & Gamble Stability: Procter & Gamble raised its dividend for the 70th consecutive year in April, and despite sluggish volume growth leading to a mere 4.7% stock price increase over five years, its 21 times earnings valuation remains attractive for risk-averse investors.
See More
Pfizer's Future Investments and Dividend Analysis
- Dividend Yield: Pfizer's recent dividend yield of 6.7% not only provides investors with a steady cash flow but also attracts long-term investors seeking income, thereby enhancing market interest in its stock.
- Analyst Rating Discrepancies: MarketWatch tracked 28 analyst ratings for Pfizer, with 9 recommending 'buy', 15 suggesting 'hold', and 3 advising 'sell', indicating a cautious market sentiment and an overall consensus to 'hold', reflecting uncertainty about future performance.
- R&D Pipeline Progress: Pfizer has 96 drugs in development, with 31 in late-stage trials, particularly the Mevpro-1 phase 3 trial for metastatic castration-resistant prostate cancer, with results expected in the second half of 2026, which could yield an upside of about $2 per share if successful, showcasing Pfizer's strategic focus in oncology.
- Acquisition and Growth Potential: By acquiring companies like Metsera to bolster its GLP-1 drug development, Pfizer is addressing upcoming patent expirations; despite current challenges, its diverse growth catalysts and robust R&D pipeline support future business growth, highlighting its potential in the weight-loss drug market.
See More
Pfizer to Host Investor Webcast at Jefferies Conference
- Webcast Announcement: Pfizer Inc. will host a webcast on June 3, 2026, at 2:00 p.m. EDT during the Jefferies Global Healthcare Conference in New York, featuring CEO Albert Bourla, which is expected to draw significant investor and public interest.
- Access Information: Investors can visit Pfizer's website to access the webcast, with registration details available starting today, ensuring participants can smoothly listen to and view this important discussion.
- Replay and Transcript: The transcript and replay of the webcast will be made available on Pfizer's website within 24 hours after the live discussion, accessible for at least 90 days, allowing investors who could not attend live to catch up on the information.
- Company Mission and Vision: Pfizer emphasizes its commitment to applying science and global resources to provide innovative therapies, highlighting its standards for quality, safety, and value in healthcare product development, showcasing its responsibility as a leading biopharmaceutical company.
See More
FDA Advisory Panel to Discuss 2026-2027 COVID Vaccine Composition
- Vaccine Target Selection: The FDA's Vaccines and Related Biological Products Advisory Committee will vote this week on whether to select the SARS-CoV-2 subvariant XFG as the target for the 2026-2027 COVID vaccines, a decision that will directly influence future vaccine development directions.
- Variant Advantage Analysis: The XFG variant, which emerged from the JN.1 variant, is currently one of the dominant COVID strains in the U.S. and internationally, possessing a growth advantage over the previously dominant LP.8.1 variant, indicating the need for timely vaccine updates to address new challenges.
- Vaccine Production Readiness: In briefing documents released ahead of the meeting, the FDA noted that all licensed COVID vaccine manufacturers have indicated their readiness to produce XFG-targeting vaccines in time for the 2026-27 vaccination season, demonstrating the industry's ability to respond quickly to new variants.
- Vaccine Design Recommendations: Based on last year's VRBPAC recommendations, the FDA has advised vaccine manufacturers to design monovalent COVID vaccines targeting JN.1, preferably LP.8.1, to ensure that vaccines are timely updated to respond to the then-dominant strains, enhancing public health response capabilities.
See More
BridgeBio Pharma Shares Drop After Downgrade by Raymond James
- Downgrade Impact: Raymond James downgraded BridgeBio Pharma (BBIO) from Outperform to Market Perform, primarily due to the anticipated impact of Pfizer's heart drug Vyndamax losing exclusivity, suggesting that BBIO's stock is unlikely to sustain upward momentum amid growing market concerns.
- Increased Competitive Risks: Analyst Martin Auster indicated that with Vyndamax's loss of exclusivity, Attruby's market share could be jeopardized, predicting that new patient starts will become challenging beyond 2031, despite BBIO's efforts to establish a differentiated clinical profile among certain prescribers.
- Market Pressure Expectations: Auster expects that as Vyndamax's exclusivity nears its end, the ATTR-CM therapy market will increasingly rely on formulary-driven dynamics, which may exert greater pressure on TTR stabilizers, potentially undermining BBIO's revenue diversification strategy.
- Price Target Removal: The analyst has removed the $89 price target for BBIO, reflecting a cautious outlook on the company's growth potential, indicating that in a payer-driven market environment, BBIO will need to exert significant efforts to maintain its market position.
See More
Dow Jones Index Celebrates 130th Anniversary with Key Stock Insights
- Dow Component Changes: Since its establishment in 1896, the Dow Jones Index has seen significant changes in its components, with recent additions like Nvidia and Amazon reflecting economic evolution, shifting investor perception from traditional low-growth stocks to a modern blend of growth and value stocks.
- Nvidia's Dividend Surge: On May 20, Nvidia raised its quarterly dividend from $0.01 to $1 per share, a staggering 2400% increase, which, despite a current yield of only 0.5%, attracts investors seeking passive income and indicates a shift towards a more stable earnings model amid surging AI demand.
- Visa's Strong Financial Performance: Despite economic uncertainties, Visa achieved a 9% increase in payment volume in its latest quarter, with valuations at 30 times free cash flow and 29 times earnings, showcasing the resilience of its business model and providing a compelling buying opportunity for investors despite stock price declines.
- Procter & Gamble's Rising Dividend Yield: Procter & Gamble raised its dividend for the 70th consecutive year in April, with a current yield of 3%, and despite challenges in volume growth, its strong brand portfolio positions it as an ideal choice for risk-averse investors, trading at a P/E of just 21, below its 10-year average of 25.4.
See More
Nvidia Makes Significant Dividend Increase
- Dividend Surge: Nvidia raised its quarterly dividend from $0.01 to $1 per share on May 20, marking a staggering 2,400% increase, which, despite a low yield of 0.5%, makes it more attractive for investors seeking passive income.
- Market Share Expansion: Nvidia has broadened its market share in data centers by delivering new rack-scale solutions, including multi-chip systems to Anthropic, OpenAI, Oracle, and SpaceX on May 18, indicating strong growth potential amid surging AI demand.
- Visa Investment Opportunity: Despite a 6.2% decline in Visa's stock year-to-date, its reasonable valuation at 30 times free cash flow and 29 times earnings presents an excellent buying opportunity, with double-digit revenue and earnings growth reflecting its robust business model.
- Procter & Gamble Stability: Procter & Gamble raised its dividend for the 70th consecutive year in April, and despite sluggish volume growth leading to a mere 4.7% stock price increase over five years, its 21 times earnings valuation remains attractive for risk-averse investors.
See More
